Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Using Regulatory Processes to Enhance Patient Care: A Conversation with Lars Dreesmann

Mar 6, 202439 minAudio

In this episode of Pharma Sessions, host Jonathan Kaskey speaks with Lars Dreesmann, the President and Site Head for Boehringer Ingelheim Fremont about how regulatory affairs can impact patient care. They explore the challenges and opportunities in the regulatory space, including the impact of technology and AI on regulatory affairs and the potential for collaboration between pharmaceutical companies. Lars shares his transition from academia to the pharmaceutical industry, the thrill ... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_01Smart risk taking for me is taking a sports analogy. You don't always want to play defense, you want to win. I think looking for opportunities of applying smart risk taking to make sure you focus on the elements which are really critical and crucial and say where less is more.

SPEAKER_00Hello, hello, and welcome to Pharma Sessions, the podcast where Metafairs professionals can learn from each other. So it's been said that a vaccine has never helped a single person, but vaccinations have saved countless lives. The point being, a medicine is not enough. It must get to patients to make the difference. My guest is Lars Drietman, president and site head for Boeringer Engelheim Fremont. We had a great conversation about regulatory processes in pharma manufacturing and how this impacts patient care.

SPEAKER_00We discussed a number of challenges and opportunities in the regulatory space, including the impact of technology on reg affairs, the potential for AI to stream regulatory processes, and collaboration amongst pharma companies in advancing treatments for patients. As always, the views here are our own and don't reflect those of our respective employers. So with that said, let's jump right in.

SPEAKER_01My name is Lars Dreesman. I'm here working for BI in California and Freemont at our manufacturing, only manufacturing site we have in the US for human pharmaceuticals. I'm with BI or Beringar since almost 17 years, so um quite some time. And the company provided me the opportunity to explore different parts of the company. So I started in manufacturing, I went to development, into quality, and then in the middle of the pandemic, I was asked if I would uh be open to relocate from Germany, where I've been based before, here to the US, to California, which yeah, we did as a family.

SPEAKER_01And since then I'm heading here our US biopharma manufacturing site in Fremont.

SPEAKER_00Wow. So you did that in the midst of COVID, and you did a cross-world move with your family. Absolutely. How was that?

SPEAKER_01Which was an endeavor on its own, right? So trying to move between continents, even right, not only countries, continents, and then adapting to the new kind of culture coming from Europe or Germany. But it was great. Looking back, there were some tough phases and days and weeks because, yeah, pandemic, everything was different, right? But especially when working like in the healthcare industry, and like we are doing, I'm doing here in manufacturing medicines, but we emphasized a little bit the purpose of what we're doing and why we are here.

SPEAKER_01I guess made it very obvious for a lot of people, if not all, most of the people around the globe. I think that was on the other hand, also like rewarding and re-reassuring about the work we're doing is a great one.

SPEAKER_00That's really interesting. So, today what we're going to talk about is regulatory processes and essentially their importance in pharmaceutical manufacturing. But before we get to all of that, pharma manufacturing is such a specific thing to devote your career to. What interested in you in this? What brought you to this field in the first place?

SPEAKER_01Many after university and I started studying biology and then continuing and doing my PhD in neurobiology, but I was always like looking for how we can apply this? What are we doing with the science and all the kind of learnings and all the biology? So turning it into a product essentially. And I think that's what made me leave academia and then switch to the industry. And for the first time, I went into the manufacturing facility and I was standing in front of those big 300-liter, I remember, stainless steel vessels full of antibody.

SPEAKER_01That that was fascinating and stunning. And then the next one, the next kind of key moment was when I figured out that some of the medicines we were manufacturing, people, friends of mine were unfortunately, but fortunately, were taking. So I had this link not only, hey, the product, that's how we turned science into product, but also, hey, we are helping people with this and making their lives better, or being you know, able to live a normal, almost normal life.

SPEAKER_01And that always fascinated me and kept me somewhere around manufacturing a little bit, with some kind of exploring different uh areas left and right, but that always kept me close to manufacturing because I I can see the product and what we are doing and who we are helping with.

SPEAKER_00Very different from being on a lab bench or publishing a paper, right? You have a physical product that is going into human bodies. It's also important, right?

SPEAKER_01Being on the lab and bench, also in our case, all the analytics we need, especially for biologicals and the framework we are operating in. But I do not want to diminish kind of the lab work and people working in in the labs and doing other work, also scientific papers still helping us throughout the life cycle of a product. We need to always apply latest science and technology because those are also the questions we get from like agencies or even sometimes patients, right? And I think that keeps us like state of the art uh and always close to the benchmark.

SPEAKER_01So it's still everyone is needed and it's all important work, it's just different perspectives and facets of it.

SPEAKER_00Yeah, absolutely. And so many of the people that I've talked to on the podcast before have been in medical affairs, and it seems like one of the big jobs of Med Affairs is to take all of that stuff and parse through all of the data and all of the various languages that might be completely inaccessible to many people who end up needing the medicine or insuring for the medicine or any part of the value chain or the prescription chain, right? And so it is fascinating. I don't mean to denigrate any piece of it. I just very recently had a had an experience where I got prescribed a drug that I was part of the commercial launch of, and I thought this is really cool.

SPEAKER_00Like this thing worked, it's successful. Hopefully it works for me. But it's just a very interesting way to see that come full circle.

SPEAKER_01Yep.

SPEAKER_00Absolutely. So from a regulatory perspective, I'll be what should can you take me through the different groups that are involved in regulatory as it relates to manufacturing?

SPEAKER_01Groups who are involved is basically when we develop or bringing a new molecule towards the market and launching it, there's this kind of like almost decade-long work before. And there are plenty of documents and data we need to compile in the end into a submission we then submit to most of the case here the FDA environments. So and I think many people and and groups along this process coming from initial development where we need the development information, even the the sequence, the genetic information from the molecule that starts there, the whole process, especially in biologics, the the process is part of the product.

SPEAKER_01So all those information we need to compile. So a lot of, if not all, kind of functions along the value stream touching it, and then in the end, you have this one regulatory, in our case, uh technical regulatory affairs for manufacturing, with overseeing this whole thing and matching what we are doing and linking it to the different kinds of sections of the submission we need to complete and compile to then ultimately submit.

SPEAKER_01So it's all the technical functions we have on site, but then overseen and managed and orchestrated by our technical regulatory, of course, tech RA in brief. Um that's our main functions. And then we work, like you mentioned earlier before, with medical affairs with our regional or US regulatory or global regulatory affairs colleagues, because some molecules, most, we're not only launching and bringing to the market in the US with FDA, we also have different or other agencies we need to work with.

SPEAKER_01So it's not only one dossier or submission, it's multiple ones. They all have certain commonalities, but different perspective, and that's when we need all those other groups to help us having the right piece of information and the right document, compile it in the right way, in the right structured way, so that it's easily accessible and could be then judged by or reviewed by the agencies.

SPEAKER_00So my experience of this has been helping or working with people as they walk through from say like a CM CMC setting setting protocols and then those going through labeling and then submission the old-fashioned way or electronic submission or what they that you're describing. Is that a fair assessment of the path of the kind of the subgroups that fall in regulatory affairs, or am I missing some components?

SPEAKER_01No, definitely. And we are, and that's why I was relating more to the CMC part because that's our core. We are delivering the C mainly the CMC section, and then you have all the other kind of elements, the clinical data, and all you mentioned before. And that's exactly the value screen through the regulatory. From a manufacturing perspective, we are primarily focusing on the CMC part because that's what we do and then contribute to the overall process.

SPEAKER_00And so when you're laying this out, are your primary goals and a bit more kind of efficiency-based, right? We're trying to reduce waste, increase safety. Are there other let me rephrase the question? How can regulatory be really strategic as you're looking to bring drugs to market as quickly as possible, as safely as possible, with maximum effectiveness? Right? Can that is it simply a matter of risk avoidance or making sure things don't go wrong, or are there areas where it can actually push things further forward faster?

SPEAKER_01I would describe it more as smart risk taking, not as risk avoidance necessarily, but smart risk taking. Because there are certain topics or areas of the information you're compiling or working with, which is they don't really change significantly even between products. It's just the standard work and stuff you need to do. So I think there are opportunities where you could be smart in terms of how detailed or like how comprehensive you know need though those chapters or sections need to be.

SPEAKER_01And then there are some more of the specifics where you really want to make sure you have the right information, especially as soon as you're tackling the safety and efficacy part of it. That's where you really want to make sure. But there's a lot of left and right now where I think it's more general and that doesn't really change. So I think it's defining the right sections or areas where you can apply the smart risk taking and saying, okay, sometimes less is more, right? And rely also perhaps on the history or track record of a certain kind of company or manufacturing site in providing certain information.

SPEAKER_01But where do we really need to make sure that we have a kind of holistic, in-depth assessment of the molecule, its safety efficacy, because in the end it's ending up in humans and patients. So again, for me, it's more smart risk taking and having the right spots where you are smart about the risks and are willing to take those, and some where you do somewhere you don't want to like compromise or be a little bit easy with respect to taking risks.

SPEAKER_00So just to get a little bit more specific, right, so that people on listening can follow along, can you provide an example of where it might not make sense to take risks, whether it's just the standard blocking and tackling that needs to be documented and accomplished versus an opportunity that you've seen to do a little bit of innovation or risk taking that's panned out?

SPEAKER_01So I think again, relating back to the CMC part and what we are doing, especially on the analytics, because we need to have a lot of biological analytics to really make sure we have the right molecule in front of us. And I think that's certain areas with the method validation and the analytics of the molecule where you don't want to necessarily compromise a lot because that's again relating directly to the safety and efficacy of the product. However, then for the manufacturing process itself, there's a lot of standard work behind manufacturing, like media preparation or running the directors or thawing the workings.

SPEAKER_01That's again certain areas, it's just standard work. You have sometimes we like also in Boering, you have platform, platform technologies, platform processes. So that's I think opportunities where sometimes less is more because the the risk which is associated with this is anyhow less and little, because again, you have the analytics at the end. So in in certain you know areas, that's where I think along manufacturing smart applying smart risks is really an opportunity. However, then as soon as it relates to we don't want to be smart or taking less or taking more risks, so to say, on skipping certain analytics as they are so critical for the safety and efficacy part of the molecule.

SPEAKER_00Yeah, that's really interesting, and it's perhaps a little bit different than what I was expecting. But it sounds like the analytics are sacrosanct, right? And they that's not an opportunity for for really any type of deviation, but it's pushing media, pushing the teams to reach those endpoints faster is where you're looking at opportunities for innovation.

SPEAKER_01And also, again, within the analytics, you have the standard sets you need to apply, and that's also opportunities like where yes, you don't need to have the full-blown, overly sophisticated set, but then what's specific to your kind of molecule, the the areas where again you have the direct based on science, the direct interaction to the efficacy and safety for patients, that's not but you have some other general kind of elements where you could say, yeah, that's anyhow like a given, or we have multiple tests anyhow along the way. So adding another yet another one, does this really make sense, or is this an opportunity to streamline and be a little bit more efficient uh with respect to the number or the magnitude in which with which you're testing, whereas you want to really make sure some other tests they need to be done, they need to be there, even though they're sometimes lengthy ones or complicated ones.

SPEAKER_01That's the ones you definitely want to have um done and included.

SPEAKER_00Yeah. It's funny. One of people that I've worked for in my career, he was actually Swiss and very like efficient regimented. And what he told me at one point is efficiency isn't figuring out how to do things faster, it's figuring out what not to do. And I thought that's always stuck with me, right? Because at a certain point, there's only so fast you can push things and do things, but oftentimes there's a lot that you might not need to be doing. So where I'm gonna ask some questions about biosimilar specifically in a bit, but just to complete this thought, where does your regulatory guidance and I asked that let me give you the context and what I'm thinking of?

SPEAKER_00At one point I was talking to somebody at a vaccine manufacturer, and they were describing like the last mile problem of getting a vaccine to communities in rural Africa and their vials smashing as they go over bumpy roads and things like that. So, how much of this process from manufacture to delivery is your group involved in?

SPEAKER_01So, for sure, our focus and primary scope is the manufacturing, but then also like you described the transport. So, like transport validation and making sure the molecules we're supplying worldwide, and we have just described there, might be bumpy roads, there might be different temperature patterns around the world. Molecules sitting at the airport or at the tarmac at I don't know 100 something Fahrenheit and some freezing cold. Those transport validation hold times, how long in which kind of condition can you hold the molecule, especially for biologics, as you typically rely on a cold chain, right?

SPEAKER_01And it's not a room or ambient temperature. So that's important elements. Um, and then shelf life aspects. How long for how long is like the best before with the molecule? So that's also definitely one of the important elements considering the shelf life and applying the different kinds of environments the molecule might find them itself in. How does this influence then the shelf life to make sure once the medication molecule arrives at the patient, it's definitely good and with the intended kind of results.

SPEAKER_01So those are primarily the areas we are overseeing and including in the data we are generating.

SPEAKER_00And how has the management of all that? Because I'm picturing in my mind again from the clinical process to sending these out to test sites across the world and then some of those laboratories, they might be jotting things down on notepads, right? And then you're hoping that they're entering information. Have you seen a shift based on technology as far as how this is all managed? Has it improved at all or continuing to improve?

SPEAKER_01Yeah, for the time I'm in the industry, almost one and a half decades, so it it changed a lot with respect to be far more digital, and and therefore the speed was different. Also, on the other hand, the downside is a little bit the overwhelming kind of amount of data points you are able to generate, and then drawing the right conclusion sometimes, that's then the downside. But in terms of being far more digital and less paper involved, and sending paper by mail, that's definitely a significant change.

SPEAKER_01But also the accessibility. I can access some of the data along transportation even with my cell phone, right? So I know you you so I can even check some of the manufacturing stuff based on cell phone or tablets, right? So I think the accessibility, the real-time as almost real-time aspect of it, that that changed a lot. Created also expectations how timely you should and need to deal with some of this data. But that's for sure where I think we just saw the beginning, and I guess not mentioning too much of the AI, artificial intelligence opportunities which are now coming and we see at the horizon.

SPEAKER_01So that will be the next shift in paradigm or paradigm shift with respect to some of those tasks at the moment. Uh, the industry we need to do, where you could even apply more smart AI ways of doing this episode is sponsored by structured meetings.

SPEAKER_00It's a team's app that turns your own teams incident into the perfect advisory board platform. Check it out at www.structured meetings.com. Yeah, and this is this it kind of feels like the natural progression of where this conversation or where this thought train would go. Because from an AI perspective, things like tracking massive amounts of data, making sure that op recognizing when there are outliers and operations aren't being followed, that seems like an ideal application.

SPEAKER_00And I'm imagining there are probably already intermediary steps where flags are being raised if things things jump out. So, what would be the true kind of AI versus what we already have with data and analytics and dashboards and the like? Where do you think there's opportunity for AI to play a significant role in this process?

SPEAKER_01So I guess at the moment, short term, I think AI, the application, is more like where we now need people, sometimes a lot of people, to compile data and generating meaningful kind of reports. That's an application where I think we see the advantages of ChatGPT and others as a language model, right? And I think that's compiling those reports. Just imagine the quality systems aspect of it. Once we have a deviation, we need to do the investigation, we have a lot of information and data compiling this in a way that it's easy to understand because then you need to show authorities and so on.

SPEAKER_01So I think that's where at the moment a lot of human brain work and power is involved. But that's something where I think that's elements where AI could help us a lot. And then you still, it's the human you need and the human brain to how to best apply it and in which areas. And I think that's what at the moment, some elements where AI they can't do it, perhaps yet, yeah. But I think that's where just gathering information, writing reports, stuff like this. You still need a human to finally review it, right?

SPEAKER_01But the first like draft of it, and creating out of those massive amounts of different data or or pieces of it, creating the first draft, that's where AI at the moment I think could be really powerful. Then still, you need human involvement to okay, does this make sense in the in the context of things and so on, and finally release it? But yeah, then it will be how do we continue to build and train those models? And I guess we're just at the cusp of exploring in which areas and how far we can take this, and then there are also kind of some scary elements of it where you think, okay, do we really want to have an artificial intelligence doing this or preparing those decisions?

SPEAKER_01So I think, yeah, it's always Balancing the pros and cons of new technologies, like we did in the past decades with so many other technologies, but getting the most out of it in the end. So I think that's an interesting topic and development, and perhaps a podcast on its own. For sure, if not many, but yeah, that's where pharma industry, healthcare industry, like so many other industries, are looking at this. For us, I guess the special feature, and we spoke regulatory, we are operating in a highly regulated framework, right?

SPEAKER_01And I think how do you apply AI in this regulated framework? Because then to what extent do we need to understand the algorithms behind, validate those? So I think those are elements where we typically were just not using equipment and use it. We need to validate and then show and then it's consistency. So I think that's okay. How do we do this in the healthcare or pharma sector? Um, that will be interesting to see.

SPEAKER_00Yeah, I think you just hit on a really important point because the stakes are higher, right? It's not a chatbot answering a customer service question on a website. It's very different from that. And what I've seen in my day-to-day is a lot of people are looking at, I think what you're referring to, they're calling human in the loop, right? Where we're having AI do maybe some of the grunt work, right? I don't need to have a human formatting this stuff. Maybe I maybe it shows up already formatted, but at this point, it still seems very important that human brains are reviewing, certainly before submission, but it's it's really it's fascinating, and it does feel, as you said, like we're on the cusp of it.

SPEAKER_00I'm just a little nervous because every time I test it out, it's just not quite what you want it to be. Yeah.

SPEAKER_01To make sure you get what you need and not something different, right? And I think that's the important learning at the moment where many people think, hey, we just are just putting this stuff in ChatGPT, and then no, it's not as easy as this, right?

SPEAKER_00So yeah, yeah, it's also going to be really interesting because you can imagine, or I would assume, that the regulatory agencies are having the similar conversation, and it's like at some point there's going to be a large amount of this that is bots chatting with each other, right? And having visibility into the algorithms again. It's a whole separate topic, but how will agencies use this, right?

SPEAKER_01You could think of, okay, do they just take the submission, load it in their FDA GPT model, whatever, and then say, okay, show me the inconsistencies in the submission. It's right. Yeah, it's in so it will be interesting to see where we're going with this.

SPEAKER_00So you had mentioned a few times the focus on biosimilars, and to be honest, my knowledge of the manufacturing process of biosimilars isn't great. I just know that it's really hard and complex and challenging. Do you see thinking about the regulatory elements of it, do you see differences dealing with biosimilars versus kind of your standard pharma product? Or is it the same approach, just more to worry about, more processes, harder, different environments to consider?

SPEAKER_01It's more of the latter, and also it's not completely different, it's more like what we usually do. I think the pinhole you need to hit the that kind of framework is just tighter because you're comparing yourself to an already existing molecule. And I think it's the difference between like small molecules, you have chemical synthesis, and you have you can with a mass spec, you understand that's the chemical structure, and that's what we need to aim for.

SPEAKER_01With a biological molecule and very complex proteins, that's different. So the magnitude and the wiggle room or or or leeway you have is just far more narrow compared to a new medical entity you have, because there you are defining your specification. You're saying, okay, that's it. However, for biosimilar, it's far narrow, and then you have already the life cycle of the existing molecule, and certain they might shrunken the window for certain specifications due to the consistency of their manufacturing or whatever.

SPEAKER_01And it's like I think for if you would ask analogy of pilots, a pilot landing like long runway, great weather conditions, so easy landing. And then you're asking, okay, and now you have those pilots, rough sea aircraft carrier, you lend me the plane here, right? So it's it's the same, it's we're landing a plane, right? But it's very different in terms of the framework and the boundary conditions you have in being successful.

SPEAKER_00That's really interesting. So, from your perspective, it's actually it it might be more challenging to make a bio similar than say a novel biologic in the first place, because you have to be identical, essentially, and there's so many variables to control. Um, so then not to get too detailed, this is just fascinating. It's if I take a step back, it's always amazing to me that any drug gets manufactured and like that it works and it can be delivered all over the world and all of this, but let alone what you're describing.

SPEAKER_00So, keeping the focus on the regulatory and the documentation and and all of that, where are there opportunities to help? If I'm listening to this and I'm in regulatory and I'm working on a bio similar, what should I be keeping in mind as I'm going to work tomorrow?

SPEAKER_01So, again, as we discussed earlier, I I think now we have the situation we have an existing molecule with an existing submission and license, even though this is proprietary knowledge, right? So it can't be disclosed, but like you're copying the whole thing, right? So you're making a similar process with the same results. So typically, as in biologics, the process is part of the product. You won't see significant deviations also here in the manufacturing process, because this would ultimately lead to a challenging outcome, saying a far different or different molecules.

SPEAKER_01And again, a lot of this technology, it's common ground. It's like everyone's doing like almost the same things. You need to understand with your media recipe and so on to keep the cells happy, manufacturing or creating the molecule you intend to do. But again, that's where those opportunities we discussed earlier with the smart risk taking. I think there are certain critical quality attributes of the molecule, CQAs, right? And I think making sure you're hitting those and you really make sure there's a certain consistency, you know, in your coming from your manufacturing process into the analytics to make sure you're meeting those CQAs.

SPEAKER_01Yeah, but the rest is again, it's more of the same. Yeah. And I think now as you submit for getting the license for an iOS similar, agencies can compare what's already out there. So there should be a way where also here we could be faster, more efficient. However, as a regulatory person in a given company like Berlin, that could be the opportunity also engage and embark in a discussion with FDA or other agencies and saying, okay, we all know this molecule works, but it's proven this for decades, and we also know the science behind, so we really want to make sure in these areas analytics we are not deviating, we we make sure it's similar.

SPEAKER_01However, the way of getting there, we just apply our standard ways, which are also licensed in multiple ways. So I think that could be more opportunities for smart risk taking, because that's again, it's it's we have a similar molecule with a similar manufacturing process with a lot of data already at hand. So I think that should give also the agency confidence to say, okay, we already know a lot about this molecule. We also saw perhaps in the past, due to the life cycle of the originator, where you need to be careful.

SPEAKER_01So there could be even eventually data sharing from the FDA perspective and saying, hey, look, we know turned out through the life cycle of the originator. You need to make sure in those areas you you really keep it tight, yeah, and that would help to accelerate the whole development, but definitely submission and bringing those uh uh therapeutic opportunities and treatment opportunities to the market a little bit faster and a little bit more efficient, to your point of earlier, not doing it faster, but doing kind of less, but still with the same result in terms of prioritizing where we really need to focus, not to sacrifice on safety and efficacy, but be reasonable about do we really need to have each and everything.

SPEAKER_00How much leeway when you start to talk about do we really need to have each thing? How much do government agencies, for example, the proving bodies give industry a voice in that? Are they receptive if people are saying, hey, here's there's a legitimate reason that we believe that this is no longer appropriate or has advanced, or is it really it comes down from the mountaintop and you follow it?

SPEAKER_01No. So agencies are open. They are most of the reviewers, they are scientists like we. So you have this common science ground, right? And I I never experienced that reviewers or agencies like FDA would not listen to you if you're bringing an argument forward with which is scientifically sound based on data and facts, because we're all the same community kind of thing, working on different ends, but it's the same community. And I think that's where I always experienced agencies here in the US, same in Europe or elsewhere, being open to have a discussion.

SPEAKER_01We could have different opinions and perspectives of it, but at least the door I experienced was always like open to have this discussion, and then you can start together, evolve a certain thought or an idea, and looking for opportunities to still have the same result, safe medication for patients, but perhaps different ways of doing it. And I think also agencies need to keep up with kind of technology, state of the art, what happens. And I think that's where they also ask us, hey, how do you do this and how do you apply that?

SPEAKER_01And how do you include this part of the latest technology into your kind of way of doing things? They want to learn from us, right? So I think that's really, I feel always an opportunity and always an open door or a phone call which is answered to exchange on those topics or meeting at conferences, meeting the FDA, we have those events, right? So where you can have those kind of discussions.

SPEAKER_00Yeah, it's been really interesting. So in my own career, I've worked a lot on the kind of the commercial side of things, and now much more in the like regulatory off documentation space. But seeing the level of collaboration that people on this side of the spectrum have across across companies within the pharmaceutical industry is really interesting, where it's like some of these goals of getting drugs to market faster or eliminating inefficiencies, right, are common, whether you're at BI or Pfizer or Amgen or whomever, right?

SPEAKER_00And so it's been really interesting with things like the fire submissions or other types of things, seeing industry saying, hey, we're making we're gonna make a cohesive argument based in science about what's needed and why that'll help us all partner. I don't know. It's you would you would assume some of these the big pharma's would be purely adversarial, but that hasn't been what I've been seeing. It's that there's a lot of collaboration.

SPEAKER_01No, it is so again, it's we all have certain overlapping like therapeutic areas also, but in the end, we're all driven by the same kind of like purpose. We have science leads us and the way to how we can help people suffering, and even though yeah, we're different companies and then agencies, in the end, we we have the opportunity here to turn science into support and help for patients. And I think that's where no one would, in the end, say, yeah, no, let's not do this. So let's better not talk to each other because hey, why would we do this?

SPEAKER_01And I think that's again based on the purpose and what we are doing. I think that's I I feel is different. And then it's still a big industry, but it's also a certain community, and a lot of people with science background, and I think it's a certain kind of people and characters you have there in a positive way, which are always open and interested. I see a lot of curiosity in most of the people working in this industry, and and I think that's what fuels a lot of this collaboration and talking to each other, and still everyone protects a little bit their own turf, but this curiosity, this interest in in and coming from the science and then understanding how we can do this differently or better, I think that's really cool and to work in this kind of industry.

SPEAKER_00Yeah, absolutely. So let me end with the question that I like to end all of these. Thinking about your job, thinking about everything we've talked about, what are you most excited about over the next, say, three to five years?

SPEAKER_01So I'm most excited about from a Beringer perspective, we have a great pipeline fueled by science, and bringing those treatment opportunities to patients and being part, overseeing a part of this value chain to the patient, that kind of excites me. Again, still turning science into a real product, standing in front of all the stainless steel we have in the facility, and always being fascinated. We really are being able to make kind of proteins with all this stuff, and in the end, helping people.

SPEAKER_01So that's what gets me out of bed each morning, and then working with all the people here on site in Buringer with the industry we just discussed. So that excites me and looking to the future, and with the leaps in technology and in scientific understanding, I'm very excited that we will see also treatment opportunities for some diseases, which at the moment we are lacking a little bit the imagination of hey, we can really cure this, not only treat, but eventually cure this.

SPEAKER_01That kind of fascinates and excites me and being happy to work in this industry.

SPEAKER_00Wonderful. So let's leave it there. But Lars, thank you so much for joining me today.

SPEAKER_01Thank you. Thanks for having me.

SPEAKER_00This episode is sponsored by structured meetings. For listeners who don't know my background, I'm a huge fan of asynchronous ad boards. I used to work as a leading provider of async adboards, and not to brag my clients did more vendor than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in teams? And the answer back then was not really. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own teams instance.

SPEAKER_00It changes teams and it changes enough to check all the boxes for what is needed for great ad boards. And also it's super fast and it saves people a ton of money.com for more info. All right, back to the show.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode